peoniflorin and Parkinson-Disease--Secondary

In the present studies, the effect of paeoniflorin (PF), one of the main compounds extracted from Paeoniae radix, in alleviating the neurological impairment following unilateral striatal 6-hydroxydopamine (6-OHDA) lesion was examined in Sprague-Dawley rats. Sub-chronic PF (2.5, 5 and 10 mg/kg, s.c., twice daily for 11 days) administration dose-dependently reduced apomorphine (APO)-induced rotation, suggesting that PF had an ameliorative effect on the 6-OHDA-induced neurological impairment. Notably, PF had no direct action on dopamine D(1) receptor or dopamine D(2) receptor indicated by the competitive binding experiments. These results suggest that PF, an active component of Paeoniae radix, might provide an opportunity to introduce a non-dopaminergic management of Parkinson's disease.

Topics: Animals; Apomorphine; Behavior, Animal; Benzazepines; Benzoates; Binding, Competitive; Bridged-Ring Compounds; Dopamine Agonists; Dopamine Antagonists; Glucosides; Hydroxydopamines; In Vitro Techniques; Male; Membranes; Microinjections; Monoterpenes; Neostriatum; Parkinson Disease, Secondary; Raclopride; Rats; Rats, Sprague-Dawley; Stereotyped Behavior